Abstract: A glaucoma filtration implant is constituted by a generally tubular body section having an oblong external diameter formed of a continuous convex curve. The device preferably has flow resistance structure provided by a portion of the internal lumen having a reduced diameter. The flow resistance structure may have a length of up to 5000 &mgr;m and a diameter in the range 15 to 50 &mgr;m, the diameter being selected so as to achieve a pressure drop along the flow resistance structure in the range 5 to 15 mm Hg. The internal conduit for liquid flow also may include a removable flow inhibitor, which can be removed after implantation by a laser, such as an ophthalmic YAG laser. The device is made of biocompatible materials.

Abstract: An improved visual acuity chart is disclosed. The ratio of the size of the optotypes of neighbouring lines on the chart is a constant and preferably the size decrement between lines is 0.1 logMAR. Each line of optotypes has two, three or four optotypes, preferably three. Crowding bars for visual acuity charts are also disclosed. These bars are spaced from the ends of row and/or above and below the top and bottom lines. The individual bars may be joined together with linking sections. The spacing form the optotypes is preferably one half the width or height of the optotypes and their breadth is preferably that of the strokes of the optotypes.

Abstract: The use of an MMP inhibitor, especially a collagenase inhibitor, in the manufacture of a medicament for the treatment of a natural or artificial tissue comprising extracellular matrix components to inhibit contraction of the tissue and methods for the treatment of tissue comprising extracellular matrix components to inhibit contraction.